产肠毒素性大肠杆菌 (ETEC)是引起幼畜、婴幼儿及旅游者腹泻的重要病原菌之一。肠毒素是其主要的毒力因子 ,包括耐热性肠毒素 (ST)和热敏感肠毒素 (L T)。STI基因和 L TB基因融合后产生的融合蛋白不仅增强了 STI 的免疫原性 ,而且降低了...产肠毒素性大肠杆菌 (ETEC)是引起幼畜、婴幼儿及旅游者腹泻的重要病原菌之一。肠毒素是其主要的毒力因子 ,包括耐热性肠毒素 (ST)和热敏感肠毒素 (L T)。STI基因和 L TB基因融合后产生的融合蛋白不仅增强了 STI 的免疫原性 ,而且降低了 STI 的生物毒性 ,这就给抗幼畜腹泻的基因工程亚单位苗开发带来了新的希望。展开更多
Management of acute diarrhea remains a global challenge, particularly in resource-limiting countries. Oral rehydration solution(ORS), a passive rehydrating therapy developed approximately 40 years ago, remains the mai...Management of acute diarrhea remains a global challenge, particularly in resource-limiting countries. Oral rehydration solution(ORS), a passive rehydrating therapy developed approximately 40 years ago, remains the mainstay treatment. Although ORS is effective for hydration, since it does not inhibit enterotoxinmediated excessive secretion, reduced absorption and compromised barrier function- the primary mechanisms of diarrhea, ORS does not offer a rapid relief of diarrhea symptom. There are a few alternative therapies available, yet the use of these drugs is limited by their expense, lack of availability and/or safety concerns. Novel anti-diarrheal therapeutic approaches, particularly those simple affordable therapies, are needed. This article explores intestinal calciumsensing receptor(Ca SR), a newly uncovered target for therapy of diarrhea. Unlike others, targeting this host antidiarrheal receptor system appears "all-inclusive": it is anti-secretory, pro-absorptive, anti-motility, and anti-inflammatory. Thus, activating Ca SR reverses changes of both secretory and inflammatory diarrheas. Considering its unique property of using simple nutrients such as calcium, polyamines, and certain amino acids/oligopeptides as activators, it is possible that through targeting of Ca SR with a combination of specific nutrients, novel oral rehydrating solutions that are inexpensive and practical to use in all countries may be developed.展开更多
文摘产肠毒素性大肠杆菌 (ETEC)是引起幼畜、婴幼儿及旅游者腹泻的重要病原菌之一。肠毒素是其主要的毒力因子 ,包括耐热性肠毒素 (ST)和热敏感肠毒素 (L T)。STI基因和 L TB基因融合后产生的融合蛋白不仅增强了 STI 的免疫原性 ,而且降低了 STI 的生物毒性 ,这就给抗幼畜腹泻的基因工程亚单位苗开发带来了新的希望。
基金Supported by The National Institute of Health NICHD,award No.K08HD079674the CDNHF/NASPGHAN foundation,award No.00102979the Children’s Miracle Network
文摘Management of acute diarrhea remains a global challenge, particularly in resource-limiting countries. Oral rehydration solution(ORS), a passive rehydrating therapy developed approximately 40 years ago, remains the mainstay treatment. Although ORS is effective for hydration, since it does not inhibit enterotoxinmediated excessive secretion, reduced absorption and compromised barrier function- the primary mechanisms of diarrhea, ORS does not offer a rapid relief of diarrhea symptom. There are a few alternative therapies available, yet the use of these drugs is limited by their expense, lack of availability and/or safety concerns. Novel anti-diarrheal therapeutic approaches, particularly those simple affordable therapies, are needed. This article explores intestinal calciumsensing receptor(Ca SR), a newly uncovered target for therapy of diarrhea. Unlike others, targeting this host antidiarrheal receptor system appears "all-inclusive": it is anti-secretory, pro-absorptive, anti-motility, and anti-inflammatory. Thus, activating Ca SR reverses changes of both secretory and inflammatory diarrheas. Considering its unique property of using simple nutrients such as calcium, polyamines, and certain amino acids/oligopeptides as activators, it is possible that through targeting of Ca SR with a combination of specific nutrients, novel oral rehydrating solutions that are inexpensive and practical to use in all countries may be developed.
